Search

Displaying results 2041 - 2050 of 9314 in total
  1. Drug

    Darolutamide

    go.drugbank.com/drugs/DB12941
    ApprovedInvestigational

    The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer. … [A189063] Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies.

  2. Drug

    Diroximel fumarate

    go.drugbank.com/drugs/DB14783
    ApprovedInvestigational

    [A187535] Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. … This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure.

  3. Drug

    Dimethyl fumarate

    go.drugbank.com/drugs/DB08908
    ApprovedInvestigational

    in response to oxidative stress. … It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated

    Synonyms: (E)-But-2-enedioic acid dimethyl esterProducts: D-FUMARIC 240 CAPSULAS DE LIBERACIÓN RETARDADA 240 MG, D-FUMARIC 120 CAPSULAS DE LIBERACION RETARDADA 120 MG
  4. Drug

    Troglitazone

    go.drugbank.com/drugs/DB00197
    ApprovedWithdrawn

    Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].

  5. Drug

    Vayarin

    go.drugbank.com/drugs/DB09328
    Approved

    Cost of the drug and patient aversion to the taste of Vayarin were significant reasons for therapy failure [L1502]. … Vayarin is a specially formulated and designed to address the distinct, previously determined lipid nutritional requirements of children with ADHD, the dietary management of which cannot be achieved with

  6. Drug

    Methylchloroisothiazolinone

    go.drugbank.com/drugs/DB14197
    Approved

    The American Contact Dermatitis Society named Methylchloroisothiazolinone the Contact Allergen of the Year for 2013. … Sensitivity to Methylchloroisothiazolinone may be identified with a clinical patch test.

  7. Drug

    Tranexamic acid

    go.drugbank.com/drugs/DB00302
    ApprovedInvestigational

    It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. … Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding.

    Products: ZYEX-T, HEAMIC-T (Tranexamic Acid Injection 100mg/mL)
  8. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    [L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261] … It is the active metabolite of [macitentan].

  9. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    It was approved by the FDA after being given the status of priority review for on July 7, 2015. … Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection

  10. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. … [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842]

    Synonyms: T-DXd, T- DXd